Table 7

Areas under the curve (AUC) for receiver operator characteristic analyses in which measurements of FEV₁ at baseline, FEV₁ at loss of control (LOC) or 28 days after steroid withdrawal, change in FEV₁ with bronchodilator at baseline, AHR as measured by PD₁₅HS and by PC₂₀AMP and Feno were used as predictors

Predictors
	EA			NEA
	ΔPC₂₀AMP	ΔFEV₁	ΔACQ	ΔPC₂₀AMP	ΔFEV₁	ΔACQ
FEV₁ (baseline)	0.308	0.613	0.254	0.305	0.849	0.387
FEV₁ (LOC)	0.426	0.818	0.411	0.315	0.865	0.379
BD response	0.435	0.609	0.549	0.429	0.616	0.470
PD₁₅HS	0.538	0.597	0.558	0.500	0.401	0.641
PC₂₀AMP	0.686	0.691	0.710	0.656	0.708	0.646
Feno	0.778	0.699	0.727	0.810	0.354	0.631

The outcomes were: change in airway hyper-responsiveness as measured by PC₂₀AMP (ΔPC₂₀AMP), change in FEV₁ (ΔFEV₁) and change in ACQ (ΔACQ) following 28+ days of inhaled fluticasone treatment in 60 patients with eosinophilic asthma (EA) (49 for PC₂₀AMP) and 28 patients with non-eosinophilic asthma (NEA). An AUC of >0.7 is considered significant.
ACQ, Asthma Control Questionnaire; BD response, bronchodilator response; FEV₁, forced expiratory volume in 1 s; Feno, fraction of exhaled nitric oxide; PC₂₀AMP, provocation concentration of adenosine monophosphate causing a 20% fall in FEV₁; PD₁₅HS, provocation dose of hypertonic saline causing a 15% fall in FEV₁.